<DOC>
	<DOCNO>NCT01469806</DOCNO>
	<brief_summary>The primary objective Registry allow track FDA approve and/or clear knee use primary , revision , unicompartmental partial total knee arthroplasty ( TKA ) . Second , desire assist orthopaedic surgeon obtain evaluate radiographic functional outcome data PFJ patient use current publish guideline . Third , within Registry , subsets data new technology collect purpose future publication . The Patello-Femoral Joint Post Market Clinical ( PFJ PMCF ) study one subset .</brief_summary>
	<brief_title>Patello-Femoral Joint Post Market Clinical Follow-up Within Knee Registry</brief_title>
	<detailed_description>To obtain preoperative , operative postoperative clinical outcome data Zimmer Gender Solutions PFJ Knee Prosthesis use primary partial knee arthroplasty knee score patient satisfaction collection use Patient Questionaire SF-12 form . Kaplan-Meir survivorship analysis device perform . Radiographic analysis device also perform 1 , 2 , 3 , 5 , 7 , 10 year follow-up . It plan resultant data pool publish evaluate surgeon .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Patient great 18 year age ; Patient selection without bias race gender ; Patient stable health able undergo surgery ; Patient patellofemoral joint ( ) affect disease process and/or injury qualify primary unilateral bilateral replacement femoral trochlea base primary diagnosis least one following : Osteoarthritis Traumatic Arthritis Polyarthritis Severe Chondrocalcinosis Salvage previously fail surgical attempt ( e.g. , arthroscopy , lateral release , cartilage transplantation ) History patellar dislocation patella fracture Dysplasiainduced patellofemoral degeneration Patient willing able cooperate prescribe postoperative therapy ; Patient willing able complete schedule followup evaluation describe Informed Consent ; Patient participate Informed Consent process sign IRB approve Informed Consent . Patient history previous prosthetic replacement device ( ) type affect knee joint ; Independent study participation , patient schedule receive treatment use Zimmer Gender Solutions Patellofemoral Joint Prosthesis ( PFJ ) . Patient acute , chronic , local systemic infection ; Patient skeletally immature ; Patient pregnant ; Patient prisoner , mentally incompetent anticipate noncompliant . Patient know allergy one constituent implant , e.g . cobalt , chromium , nickel , etc . ; Patient Rheumatoid Arthritis ( RA ) AND ulcer skin OR history recurrent breakdown skin ; Patient neuropathic arthropathy , neuromuscular disorder , neurologic condition , vascular disorder , systemic disease and/or condition affect low limb function and/or could contribute prosthesis instability , prosthesis fixation failure , and/or complication postoperative care ; Patient Body Mass Index ( BMI ) great 40 ; Patient insufficient native bone stock operative joint ( e.g . osteoporosis , osteonecrosis , tumor , cyst , etc. ) . Note : Bone void filler NOT consider native bone stock , even autograft use ; Patient severe instability , maltracking , malalignment patella , patellofemoral , and/or tibiofemoral joint ; Patient patellectomy affect joint , include previous patellectomy , patellectomy perform simultaneous study PFA , schedule patellectomy ; Patient insufficient meniscus and/or ligament structure ( e.g . nonfunctional/absent ACL and/or PCL ) ; Patient exhibit tibiofemoral degeneration and/or Outerbridge grade great equal 3 EITHER : one ( medial lateral ) tibiofemoral compartment treat simultaneous compatible Zimmer unicompartmental knee replacement ; OR ( medial AND lateral ) tibiofemoral compartment , regardless treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>